Dr. Reddy’s Laboratories Ltd. announced today that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax®(Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).
The Angiomax® brand and generic had U.S. sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health*.
Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials.
Angiomax® is a registered trademark of The Medicines Company.
